Income Statement Genmab A/S

Stocks

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe Other stock markets 04:45:04 12/06/2026 pm IST			5-day change	1st Jan Change
1,623.00 ^DKK	+0.40%		+0.43%	-20.18%

11/06	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
11/06	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

a5.wYLOPkJfB82ONrhRnJuK_ezNxEHXKMnjD8oUpR9Mre0.hLesegMYRbW7f8Eo3uLwosG4jAaCGfu7YoVAzE4E64So04RUChp0_NRM8Q

Published financial data: GENMAB A/S

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025 (USD)
Revenues	848.2Cr	1.46TCr	1.65TCr	2.15TCr	372Cr
Total Revenues	848.2Cr	1.46TCr	1.65TCr	2.15TCr	372Cr
Cost of Goods Sold, Total	-	-	23Cr	98Cr	24Cr
Gross Profit	848.2Cr	1.46TCr	1.62TCr	2.05TCr	348.2Cr
Selling General & Admin Expenses, Total	128.3Cr	267.6Cr	329.7Cr	379Cr	63Cr
R&D Expenses	418.1Cr	552.4Cr	763Cr	967.2Cr	160.6Cr
Other Operating Expenses, Total	546.4Cr	820Cr	1.09TCr	1.35TCr	223.2Cr
Operating Income	301.8Cr	639.5Cr	532.1Cr	707.9Cr	125Cr
Interest Expense, Total	-1.3Cr	-2.1Cr	-2.7Cr	-12Cr	-6.1Cr
Interest And Investment Income	20Cr	32Cr	94Cr	100Cr	14Cr
Net Interest Expenses	18Cr	30Cr	91Cr	88Cr	7.7Cr
Currency Exchange Gains (Loss)	147Cr	103.4Cr	-89Cr	133.9Cr	-30L
Other Non Operating Income (Expenses)	-	-	-	-	-
EBT, Excl. Unusual Items	467.2Cr	773.2Cr	534.4Cr	929.3Cr	132.4Cr
Merger & Related Restructuring Charges	-	-	-	-30Cr	-18Cr
Gain (Loss) On Sale Of Investments	-69Cr	-66Cr	29Cr	25Cr	6.5Cr
Asset Writedown	-	-3.8Cr	-	-7.6Cr	-
EBT, Incl. Unusual Items	398.3Cr	703.5Cr	563.7Cr	916.4Cr	120.4Cr
Income Tax Expense	98Cr	151.3Cr	128.5Cr	132Cr	24Cr
Earnings From Continuing Operations	300.8Cr	552.2Cr	435.2Cr	784.4Cr	96Cr
Net Income to Company	300.8Cr	552.2Cr	435.2Cr	784.4Cr	96Cr
Net Income - (IS)	300.8Cr	552.2Cr	435.2Cr	784.4Cr	96Cr
Net Income to Common Incl Extra Items	300.8Cr	552.2Cr	435.2Cr	784.4Cr	96Cr
Net Income to Common Excl. Extra Items	300.8Cr	552.2Cr	435.2Cr	784.4Cr	96Cr
Per Share Items
Net EPS - Basic	46	84.45	66.64	122.21	15.49
Basic EPS - Continuing Operations	46	84.45	66.64	122.21	15.49
Basic Weighted Average Shares Outstanding	6.54Cr	6.54Cr	6.53Cr	6.42Cr	6.22Cr
Net EPS - Diluted	45.54	83.65	66.02	121.36	15.37
Diluted EPS - Continuing Operations	45.54	83.65	66.02	121.36	15.37
Diluted Weighted Average Shares Outstanding	6.6Cr	6.6Cr	6.59Cr	6.46Cr	6.27Cr
Normalized Basic EPS	44.65	73.91	51.14	90.49	13.31
Normalized Diluted EPS	44.21	73.21	50.67	89.86	13.2
American Depositary Receipts Ratio (ADR)	0.1	0.1	0.1	0.1	0.1
Supplemental Items
EBITDA	326.6Cr	671.9Cr	556.1Cr	739Cr	129Cr
EBITA	310.2Cr	646.5Cr	537.6Cr	715.7Cr	125.2Cr
EBIT	301.8Cr	639.5Cr	532.1Cr	707.9Cr	125Cr
EBITDAR	326.7Cr	-	-	-	-
Effective Tax Rate - (Ratio)	24.48	21.51	22.8	14.4	20.02
Current Domestic Taxes	97Cr	149.8Cr	-	-	-
Total Current Taxes	97Cr	149.8Cr	130.1Cr	179.9Cr	26Cr
Deferred Domestic Taxes	70L	1.5Cr	-	-	-
Total Deferred Taxes	70L	1.5Cr	-1.6Cr	-48Cr	-1.2Cr
Normalized Net Income	292Cr	483.25Cr	334Cr	580.81Cr	83Cr
Interest on Long-Term Debt	1.3Cr	2.1Cr	2.7Cr	12Cr	6.1Cr
Supplemental Operating Expense Items
General and Administrative Expenses	-	-	-	-	-
Research And Development Expense From Footnotes	418.1Cr	556.2Cr	763Cr	974.8Cr	160.6Cr
Net Rental Expense, Total	10L	-	-	-	-
Imputed Operating Lease Interest Expense	3L	-	-	-	-
Imputed Operating Lease Depreciation	7L	-	-	-	-
Stock-Based Comp., G&A Exp. (Total)	-	-	-	-	-
Stock-Based Comp., Other (Total)	31Cr	44Cr	59Cr	72Cr	13Cr
Total Stock-Based Compensation	31Cr	44Cr	59Cr	72Cr	13Cr

Fiscal Period: December	2021	2022	2023	2024	2025 (USD)
Assets
Cash And Equivalents	895.7Cr	989.3Cr	1.49TCr	985.8Cr	171.5Cr
Short Term Investments	1.04TCr	1.24TCr	1.33TCr	1.12TCr	-
Total Cash And Short Term Investments	1.93TCr	2.23TCr	2.81TCr	2.11TCr	171.5Cr
Accounts Receivable, Total	336.7Cr	591Cr	494.7Cr	659Cr	111.2Cr
Other Receivables	3.1Cr	14Cr	-	10Cr	4Cr
Total Receivables	339.8Cr	605.3Cr	494.7Cr	669.1Cr	115.2Cr
Inventory	-	-	5.7Cr	6.2Cr	1.8Cr
Total Current Assets	2.27TCr	2.84TCr	3.31TCr	2.79TCr	288.5Cr
Gross Property Plant And Equipment	134.3Cr	181.7Cr	231.7Cr	272.8Cr	44Cr
Accumulated Depreciation	-37Cr	-50Cr	-68Cr	-84Cr	-16Cr
Net Property Plant And Equipment	98Cr	132.2Cr	164.1Cr	189.1Cr	28Cr
Long-term Investments	37Cr	13Cr	13Cr	23Cr	3.7Cr
Goodwill	-	-	-	253.5Cr	36Cr
Other Intangibles, Total	25Cr	15Cr	10Cr	1.23TCr	912.3Cr
Accounts Receivable Long-Term	2.7Cr	4.8Cr	6.2Cr	5.2Cr	2.2Cr
Deferred Tax Assets Long-Term	26Cr	25Cr	21Cr	91Cr	17Cr
Total Assets	2.46TCr	3.03TCr	3.53TCr	4.58TCr	1.29TCr
Liabilities
Accounts Payable, Total	35Cr	-	-	-	-
Accrued Expenses, Total	30Cr	-	-	-	-
Current Portion of Long-Term Debt	-	-	-	-	27Cr
Current Portion of Leases	6.2Cr	7.4Cr	9Cr	9.2Cr	1.8Cr
Current Income Taxes Payable	-	-	5.4Cr	171Cr	4.3Cr
Unearned Revenue Current, Total	2.6Cr	3.3Cr	3.3Cr	2.4Cr	2.4Cr
Other Current Liabilities	83Cr	171.6Cr	230.7Cr	348.2Cr	106.9Cr
Total Current Liabilities	156.8Cr	182.3Cr	248.4Cr	530.8Cr	142.7Cr
Long-Term Debt	-	-	-	-	500.1Cr
Long-Term Leases	36Cr	52Cr	68Cr	94Cr	13Cr
Unearned Revenue Non Current	49Cr	48Cr	48Cr	48Cr	9.5Cr
Deferred Tax Liability Non Current	-	-	-	235.9Cr	36Cr
Other Non Current Liabilities	1.3Cr	1.1Cr	3.5Cr	3Cr	50L
Total Liabilities	243.1Cr	283.7Cr	367.9Cr	911.4Cr	702.6Cr
Common Stock, Total	6.6Cr	6.6Cr	6.6Cr	6.6Cr	1Cr
Additional Paid In Capital	1.2TCr	1.23TCr	1.25TCr	1.26TCr	192Cr
Retained Earnings	1TCr	1.5TCr	1.9TCr	2.36TCr	409.8Cr
Comprehensive Income and Other	8.1Cr	9.8Cr	6Cr	49Cr	-18Cr
Total Common Equity	2.22TCr	2.74TCr	3.16TCr	3.67TCr	584.7Cr
Total Equity	2.22TCr	2.74TCr	3.16TCr	3.67TCr	584.7Cr
Total Liabilities And Equity	2.46TCr	3.03TCr	3.53TCr	4.58TCr	1.29TCr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	6.54Cr	6.54Cr	6.53Cr	6.35Cr	6.16Cr
ECS Total Common Shares Outstanding	6.54Cr	6.54Cr	6.53Cr	6.35Cr	6.16Cr
Book Value / Share	339.23	419.77	483.85	577.54	94.89
Tangible Book Value	2.19TCr	2.73TCr	3.15TCr	2.18TCr	-363.1Cr
Tangible Book Value Per Share	335.35	417.54	482.3	343.39	-58.93
Total Debt	42Cr	60Cr	77Cr	102.9Cr	542.6Cr
Net Debt	-1.89TCr	-2.17TCr	-2.74TCr	-2.01TCr	371.1Cr
Debt Equivalent Oper. Leases	80L	-	-	-	-
Account Code - Inventory Valuation	3	3	3	5	5
Inventories - Raw Materials, Total	-	-	1.4Cr	40L	60L
Inventories - Finished Goods, Total	-	-	5.9Cr	7.9Cr	1.3Cr
Machinery, Total	54Cr	65Cr	91Cr	99Cr	18Cr
Full Time Employees	1.21T	1.66T	2.2T	2.63T	2.97T

Fiscal Period: December	2021	2022	2023	2024	2025 (USD)
Net Income	300.8Cr	552.2Cr	435.2Cr	784.4Cr	96Cr
Depreciation & Amortization - CF	22Cr	33Cr	18Cr	34Cr	5.5Cr
Amortization of Goodwill and Intangible Assets - (CF)	8.4Cr	7Cr	5.5Cr	7.8Cr	20L
Depreciation & Amortization, Total	30Cr	40Cr	24Cr	41Cr	5.7Cr
Amortization of Deferred Charges, Total - (CF)	-	-	-	-	1.4Cr
(Gain) Loss From Sale Of Asset	-	-	-	-	-
(Gain) Loss on Sale of Investments - (CF)	69Cr	66Cr	-29Cr	-25Cr	-6.5Cr
Asset Writedown & Restructuring Costs	-	3.8Cr	-	12Cr	3.2Cr
Stock-Based Compensation (CF)	31Cr	44Cr	59Cr	72Cr	13Cr
Other Operating Activities, Total	-131.3Cr	-121.4Cr	113.3Cr	-34Cr	-17Cr
Change In Accounts Receivable	-107.4Cr	-221.3Cr	80Cr	-159Cr	-17Cr
Change In Inventories	-	-	-5.7Cr	-50L	-90L
Change In Accounts Payable	30Cr	28Cr	62Cr	86Cr	40Cr
Change in Unearned Revenues	-	-	-	-	-
Cash from Operations	222.8Cr	391.2Cr	738Cr	777.1Cr	118.6Cr
Capital Expenditure	-25Cr	-32Cr	-37Cr	-19Cr	-3.7Cr
Cash Acquisitions	-	-	-	-1.22TCr	-721.5Cr
Sale (Purchase) of Intangible assets	-	-	-1Cr	-12Cr	-1.8Cr
Investment in Marketable and Equity Securities, Total	-71Cr	-244.4Cr	-91Cr	264.3Cr	162.7Cr
Cash from Investing	-96Cr	-276.1Cr	-128.2Cr	-990.7Cr	-564.3Cr
Long-Term Debt Issued, Total	-	-	-	-	550Cr
Total Debt Issued	-	-	-	-	550Cr
Long-Term Debt Repaid, Total	-5.8Cr	-7.3Cr	-9.1Cr	-6Cr	-1.3Cr
Total Debt Repaid	-5.8Cr	-7.3Cr	-9.1Cr	-6Cr	-1.3Cr
Issuance of Common Stock	14Cr	28Cr	15Cr	13Cr	2.3Cr
Repurchase of Common Stock	-50Cr	-100Cr	-67Cr	-398.8Cr	-45Cr
Other Financing Activities, Total	-	-	-	-	-27Cr
Cash from Financing	-42Cr	-79Cr	-61Cr	-391.9Cr	478.9Cr
Foreign Exchange Rate Adjustments	85Cr	57Cr	-52Cr	104.6Cr	30L
Net Change in Cash	169.7Cr	94Cr	497.4Cr	-500.9Cr	34Cr
Supplemental Items
Cash Interest Paid	1.2Cr	1.6Cr	2.5Cr	3.5Cr	1Cr
Cash Income Tax Paid (Refund)	74Cr	158.3Cr	106.7Cr	34Cr	46Cr
Levered Free Cash Flow	184.91Cr	209.18Cr	529.38Cr	625.24Cr	106.81Cr
Unlevered Free Cash Flow	185.72Cr	210.49Cr	531.06Cr	632.74Cr	110.62Cr
Change In Net Working Capital	39Cr	241.2Cr	-153.5Cr	-107.3Cr	-18Cr
Net Debt Issued / Repaid	-5.8Cr	-7.3Cr	-9.1Cr	-6Cr	548.7Cr

Fiscal Period: December	2021	2022	2023	2024	2025 (USD)
Profitability
Return on Assets	8.24	14.56	10.17	10.91	8.1
Return on Total Capital	8.97	15.78	11.04	12.62	9.44
Return On Equity %	14.56	22.25	14.78	22.97	17.53
Return on Common Equity	14.56	22.25	14.78	22.97	17.53
Margin Analysis
Gross Profit Margin %	100	100	98.63	95.42	93.6
SG&A Margin	15.13	18.34	20.01	17.61	16.83
EBITDA Margin %	38.5	46.04	33.76	34.33	34.68
EBITA Margin %	36.57	44.3	32.63	33.25	33.66
EBIT Margin %	35.58	43.82	32.3	32.89	33.6
Income From Continuing Operations Margin %	35.46	37.83	26.42	36.44	25.89
Net Income Margin %	35.46	37.83	26.42	36.44	25.89
Net Avail. For Common Margin %	35.46	37.83	26.42	36.44	25.89
Normalized Net Income Margin	34.43	33.11	20.27	26.98	22.24
Levered Free Cash Flow Margin	21.8	14.33	32.13	29.05	28.71
Unlevered Free Cash Flow Margin	21.9	14.42	32.24	29.39	29.74
Asset Turnover
Asset Turnover	0.37	0.53	0.5	0.53	0.39
Fixed Assets Turnover	9.91	12.71	11.12	12.19	13.65
Receivables Turnover (Average Receivables)	2.91	3.15	3.09	3.73	3.66
Inventory Turnover (Average Inventory)	-	-	-	16.55	17.63
Short Term Liquidity
Current Ratio	14.5	15.57	13.34	5.25	2.02
Quick Ratio	14.5	15.57	13.32	5.24	2.01
Operating Cash Flow to Current Liabilities	1.42	2.15	2.97	1.46	0.83
Days Sales Outstanding (Average Receivables)	125.44	116	118.08	98.08	99.84
Days Outstanding Inventory (Average Inventory)	-	-	-	22.11	20.7
Long Term Solvency
Total Debt/Equity	1.91	2.18	2.44	2.8	92.8
Total Debt / Total Capital	1.88	2.13	2.38	2.73	48.13
LT Debt/Equity	1.64	1.91	2.15	2.55	87.82
Long-Term Debt / Total Capital	1.6	1.87	2.1	2.48	45.55
Total Liabilities / Total Assets	9.87	9.37	10.43	19.89	54.58
EBIT / Interest Expense	232.15	304.52	197.07	58.99	20.49
EBITDA / Interest Expense	255.54	323.48	205.96	62.43	21.43
(EBITDA - Capex) / Interest Expense	236.15	308.38	192.41	60.88	20.82
Total Debt / EBITDA	0.13	0.09	0.14	0.14	4.15
Net Debt / EBITDA	-5.69	-3.2	-4.92	-2.68	2.84
Total Debt / (EBITDA - Capex)	0.14	0.09	0.15	0.14	4.27
Net Debt / (EBITDA - Capex)	-6.16	-3.36	-5.27	-2.75	2.92
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-16.11	72.07	13.57	30.67	19.19
Gross Profit, 1 Yr. Growth %	-16.11	72.07	12.02	26.42	16.92
EBITDA, 1 Yr. Growth %	-50.25	105.73	-14.72	33.66	22.62
EBITA, 1 Yr. Growth %	-51.86	108.41	-15.67	33.93	22.99
EBIT, 1 Yr. Growth %	-52.36	111.9	-15.61	33.04	23.15
Earnings From Cont. Operations, 1 Yr. Growth %	-36.78	83.58	-20.18	80.24	-15
Net Income, 1 Yr. Growth %	-36.78	83.58	-20.18	80.24	-15
Normalized Net Income, 1 Yr. Growth %	-7.54	65.5	-30.07	73.9	7.38
Diluted EPS Before Extra, 1 Yr. Growth %	-36.93	83.68	-20.06	83.82	-12.32
Accounts Receivable, 1 Yr. Growth %	36.7	75.53	-13.39	33.21	20.48
Inventory, 1 Yr. Growth %	-	-	-	8.77	100
Net Property, Plant and Equip., 1 Yr. Growth %	32.47	35.59	24.13	15.23	5.66
Total Assets, 1 Yr. Growth %	16.48	22.95	17.17	29.82	100.7
Tangible Book Value, 1 Yr. Growth %	16.82	24.4	16.12	-30.75	-218.89
Common Equity, 1 Yr. Growth %	16.08	23.63	15.86	16.09	13.82
Cash From Operations, 1 Yr. Growth %	-65.37	75.58	88.65	5.3	5.33
Capital Expenditures, 1 Yr. Growth %	-17.92	25.79	15.46	-48.91	37.04
Levered Free Cash Flow, 1 Yr. Growth %	-60.57	13.12	163.04	17.48	16.72
Unlevered Free Cash Flow, 1 Yr. Growth %	-60.45	13.33	162.17	17.92	19.42
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	25.73	20.14	39.9	21.82	24.76
Gross Profit, 2 Yr. CAGR %	25.73	20.14	38.94	19	21.54
EBITDA, 2 Yr. CAGR %	8.45	1.34	32.93	6.18	26.83
EBITA, 2 Yr. CAGR %	6.46	0.33	33.05	5.69	27.1
EBIT, 2 Yr. CAGR %	6.96	0.65	34.23	6.28	27.25
Earnings From Cont. Operations, 2 Yr. CAGR %	17.84	7.73	21.32	19.95	23.54
Net Income, 2 Yr. CAGR %	17.84	7.73	21.32	19.95	23.54
Normalized Net Income, 2 Yr. CAGR %	28.04	23.97	7.7	10.56	25.7
Diluted EPS Before Extra, 2 Yr. CAGR %	15.68	7.63	21.44	21.22	26.66
Accounts Receivable, 2 Yr. CAGR %	6.12	54.9	21.21	7.41	23.17
Inventory, 2 Yr. CAGR %	-	-	-	-	50
Net Property, Plant and Equip., 2 Yr. CAGR %	53.46	34.02	29.73	19.6	7.12
Total Assets, 2 Yr. CAGR %	27.52	19.67	19.71	23.33	56.86
Tangible Book Value, 2 Yr. CAGR %	27.12	20.55	19.83	-10.33	-11.84
Common Equity, 2 Yr. CAGR %	25.7	19.8	19.34	15.98	11.69
Cash From Operations, 2 Yr. CAGR %	29.62	-22.02	82	40.94	5.23
Capital Expenditures, 2 Yr. CAGR %	78.6	1.62	20.51	-23.19	-16.45
Levered Free Cash Flow, 2 Yr. CAGR %	68.36	-33.11	76.54	71.59	17.18
Unlevered Free Cash Flow, 2 Yr. CAGR %	68.16	-32.95	76.4	71.64	18.77
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	41.01	39.59	17.67	36.75	17.72
Gross Profit, 3 Yr. CAGR %	41.01	39.59	17.13	34.63	15.15
EBITDA, 3 Yr. CAGR %	30.55	34.25	-5.28	32.92	7.77
EBITA, 3 Yr. CAGR %	29.15	33.18	-5.75	33.07	7.52
EBIT, 3 Yr. CAGR %	29.8	34.33	-5.54	33.83	8.26
Earnings From Cont. Operations, 3 Yr. CAGR %	26.9	36.61	-2.93	38.43	3.96
Net Income, 3 Yr. CAGR %	26.9	36.61	-2.93	38.43	3.96
Normalized Net Income, 3 Yr. CAGR %	42.25	39.47	2.03	26.35	3.47
Diluted EPS Before Extra, 3 Yr. CAGR %	24.27	34.96	-2.94	39.43	5.78
Accounts Receivable, 3 Yr. CAGR %	36.39	25.5	26.17	25.09	7.39
Net Property, Plant and Equip., 3 Yr. CAGR %	81.9	47.26	30.64	24.71	10.45
Total Assets, 3 Yr. CAGR %	42.78	25.98	18.62	22.99	39.57
Tangible Book Value, 3 Yr. CAGR %	42.74	26.21	18.82	-0.19	-5.23
Common Equity, 3 Yr. CAGR %	40.43	25.01	18.24	18.25	10.88
Cash From Operations, 3 Yr. CAGR %	29.96	43.42	4.68	51.65	24.47
Capital Expenditures, 3 Yr. CAGR %	51.83	58.91	6.03	-9.47	-9.45
Levered Free Cash Flow, 3 Yr. CAGR %	471.03	47.46	4.23	54.4	47.35
Unlevered Free Cash Flow, 3 Yr. CAGR %	471.86	47.44	4.29	54.77	48.52
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	36.1	43.9	40.35	32.03	18.54
Gross Profit, 5 Yr. CAGR %	36.1	43.9	39.96	30.8	16.98
EBITDA, 5 Yr. CAGR %	24.46	36.58	30.52	21.62	4.63
EBITA, 5 Yr. CAGR %	23.4	35.76	30.14	21.2	4.4
EBIT, 5 Yr. CAGR %	23.44	36.16	30.99	21.83	4.72
Earnings From Cont. Operations, 5 Yr. CAGR %	20.44	37.99	24.21	29.35	5.18
Net Income, 5 Yr. CAGR %	20.44	37.99	24.21	29.35	5.18
Normalized Net Income, 5 Yr. CAGR %	32.61	47.55	26.91	26.67	10.85
Diluted EPS Before Extra, 5 Yr. CAGR %	18.83	36.32	22.71	28.96	6.25
Accounts Receivable, 5 Yr. CAGR %	28.11	59.14	30.11	17.12	23.49
Net Property, Plant and Equip., 5 Yr. CAGR %	97.81	63.42	58.9	35.5	19.33
Total Assets, 5 Yr. CAGR %	36.28	35.61	33.06	24.78	31.1
Tangible Book Value, 5 Yr. CAGR %	36.41	34.73	33.1	9.95	4.22
Common Equity, 5 Yr. CAGR %	35.68	34.34	31.58	21.17	14.23
Cash From Operations, 5 Yr. CAGR %	46.72	19.74	48.7	42.43	3.24
Capital Expenditures, 5 Yr. CAGR %	83.07	29.07	38.43	18.81	-5.18
Levered Free Cash Flow, 5 Yr. CAGR %	85.22	12.87	251.04	57.15	7.76
Unlevered Free Cash Flow, 5 Yr. CAGR %	85.44	12.98	251.26	57.31	8.49